DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health, oncology, and infectious diseases. Through investing in cutting-edge technologies and molecular biology, DALTONbio has established leading positions in the clinical diagnosis and screening of cervical cancer and endometrial carcinoma. We are committed to people's health, particularly women's well-being, through investing in our people, our business, science & technology, and various initiatives for the world.

DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening. As of 2022, DH HPV tests have served the health of over 20 million women.

DALTONbio provides exceptional triage management for those at high risk for cervical cancer through its p16/Ki-67 dual immunocytochemical staining tests (DC series), liquid-based cytology (LBC) test, liquid-based cytology slide processor, and fully-automated immunocytochemistry staining system (CINdi欣媂 system from DALTONbio). The DC p16/Ki-67 test and the LBC test are valuable in identifying cervical CIN2+ lesions. The DC p16/Ki-67 test, either used alone or together with the LBC test, is a sensitive and efficient triage approach for further diagnosis such as colposcopy among HPV-positive women.

Our exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.